|
US7597886B2
(en)
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
US6225290B1
(en)
*
|
1996-09-19 |
2001-05-01 |
The Regents Of The University Of California |
Systemic gene therapy by intestinal cell transformation
|
|
US20030129750A1
(en)
*
|
1998-02-05 |
2003-07-10 |
Yitzhack Schwartz |
Homing of donor cells to a target zone in tissue using active therapeutics or substances
|
|
US7749215B1
(en)
*
|
1998-02-05 |
2010-07-06 |
Biosense, Inc. |
Intracardiac cell delivery and cell transplantation
|
|
US20030113303A1
(en)
*
|
1998-02-05 |
2003-06-19 |
Yitzhack Schwartz |
Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
|
|
AU3072799A
(en)
|
1998-03-19 |
1999-10-11 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
|
WO1999049029A1
(en)
*
|
1998-03-20 |
1999-09-30 |
Benitec Australia Ltd |
Control of gene expression
|
|
AUPP249298A0
(en)
|
1998-03-20 |
1998-04-23 |
Ag-Gene Australia Limited |
Synthetic genes and genetic constructs comprising same I
|
|
BR9909918A
(pt)
*
|
1998-05-06 |
2000-12-26 |
Upjohn Co |
Método para a liberação de um hormÈnio de crescimento ou citocina de proteìna, peptìdeo ou polipeptìdeo fisiologicamente ativos a um vertebrado não-humano
|
|
JPH11335269A
(ja)
*
|
1998-05-19 |
1999-12-07 |
Hisamitsu Pharmaceut Co Inc |
遺伝子関連医薬の経口投与固形製剤
|
|
EP1889914A1
(en)
*
|
1999-02-19 |
2008-02-20 |
Engene, Inc. |
Compositions for gene therapy of diabetes
|
|
US6503887B1
(en)
*
|
1999-02-19 |
2003-01-07 |
Matthew During |
Peroral gene therapy of diabetes and obesity
|
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
DK1159415T3
(da)
*
|
1999-03-04 |
2010-05-03 |
Revivicor Inc |
Genetisk modifikation af somatiske celler og anvendelse deraf
|
|
US6423885B1
(en)
|
1999-08-13 |
2002-07-23 |
Commonwealth Scientific And Industrial Research Organization (Csiro) |
Methods for obtaining modified phenotypes in plant cells
|
|
US6953658B2
(en)
|
2000-03-09 |
2005-10-11 |
Diadexus, Inc. |
Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
|
|
DK1274464T3
(da)
|
2000-03-13 |
2012-01-23 |
Engene Inc |
Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
|
|
PT1309726E
(pt)
*
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
|
EP2206720A1
(en)
|
2000-04-12 |
2010-07-14 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
GB0010630D0
(en)
*
|
2000-05-04 |
2000-06-21 |
Univ Wales Medicine |
Sequence
|
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
WO2002000939A2
(en)
|
2000-06-28 |
2002-01-03 |
Diadexus, Inc. |
Method of diagnosing, monitoring, staging, imaging and treating colon cancer
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
US20020151068A1
(en)
*
|
2001-01-03 |
2002-10-17 |
Board Of Regents, The University Of Texas System |
Compositions and methods for the diagnosis and treatment of organophosphate toxicity
|
|
JP2005503116A
(ja)
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
|
|
AU2002338345A1
(en)
*
|
2001-04-04 |
2002-10-21 |
Digital Gene Technologies, Inc. |
Genes expressed in intestinal epithelium and peyer's patch m cells
|
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
AU2002311777A1
(en)
*
|
2001-04-17 |
2002-10-28 |
Genetix Pharmaceuticals, Inc. |
Method of treating arthritis using lentiviral vectors in gene therapy
|
|
EP1404713A4
(en)
*
|
2001-05-24 |
2004-09-22 |
Human Dna Technology Inc |
NEW KERATINOCYTE GROWTH FACTOR 2 ANALOG IN HAIR FOLLICULES
|
|
AU2002365188A1
(en)
*
|
2001-11-07 |
2003-07-30 |
Musc Foundation For Research Development |
Nucleic acid delivery and expression
|
|
US20030135195A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Oscar Jimenez |
Highly lubricious hydrophilic coating utilizing dendrimers
|
|
DE60336754D1
(de)
|
2002-02-14 |
2011-05-26 |
Univ R |
Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
|
|
WO2003104439A2
(en)
*
|
2002-03-12 |
2003-12-18 |
Surface Logix, Inc. |
Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
|
|
US7374930B2
(en)
*
|
2002-05-21 |
2008-05-20 |
Expression Genetics, Inc. |
GLP-1 gene delivery for the treatment of type 2 diabetes
|
|
US7977098B2
(en)
|
2002-05-31 |
2011-07-12 |
Children's Hospital Medical Center |
Antigenic binding patterns of norovirus to human histo-blood group antigens
|
|
DE60336063D1
(de)
*
|
2002-05-31 |
2011-03-31 |
Childrens Hosp Medical Center |
Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
|
|
US20040016013A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
|
|
US20040014704A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent induces tolerance
|
|
US20040014698A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
|
CA2503437A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Biogen Idec Ma Inc. |
High expression locus vector based on ferritin heavy chain gene locus
|
|
US20050026859A1
(en)
*
|
2002-11-12 |
2005-02-03 |
John Hilfinger |
Methods and compositions of gene delivery agents for systemic and local therapy
|
|
US20080026077A1
(en)
*
|
2002-11-12 |
2008-01-31 |
John Hilfinger |
Methods and compositions of gene delivery agents for systemic and local therapy
|
|
WO2005032574A1
(en)
*
|
2003-10-03 |
2005-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway
|
|
US20050208032A1
(en)
*
|
2004-01-16 |
2005-09-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
|
CA2634080A1
(en)
*
|
2005-12-20 |
2007-06-28 |
Arana Therapeutics Limited |
Anti-inflammatory dab
|
|
AU2007285472B2
(en)
*
|
2006-03-30 |
2013-10-24 |
Engene, Inc. |
Non-viral compositions and methods for transfecting gut cells in vivo
|
|
JP2011504366A
(ja)
*
|
2007-11-26 |
2011-02-10 |
プラント バイオサイエンス リミティド |
エンドリシン活性を有する新規ポリペプチド及びその使用
|
|
EP2296683B1
(en)
|
2008-06-03 |
2017-01-25 |
University Of Rochester |
AvrA PROTEIN FOR TREATING INFLAMMATORY INTESTINAL DISEASE AND MANAGING SYMPTOMS THEREOF
|
|
US20100068233A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Modifiable dosage form
|
|
US20100068152A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Ex vivo modifiable particle or polymeric based final dosage form
|
|
US20100069821A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Ex vivo modifiable medicament release-sites final dosage form
|
|
US20100068235A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete LLC, a limited liability corporation of Deleware |
Individualizable dosage form
|
|
US20100068153A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Ex vivo activatable final dosage form
|
|
US20100068256A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Ex vivo modifiable medicament release-substance
|
|
US20100068275A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Personalizable dosage form
|
|
US20100068254A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Mahalaxmi Gita Bangera |
Modifying a medicament availability state of a final dosage form
|
|
US20100069887A1
(en)
*
|
2008-09-16 |
2010-03-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Multiple chamber ex vivo adjustable-release final dosage form
|
|
GB0908949D0
(en)
|
2009-05-26 |
2009-07-01 |
Plant Bioscience Ltd |
Novel polypeptides having endolysin activity and uses thereof
|
|
EP2440582B1
(en)
|
2009-06-09 |
2018-11-07 |
Children's Hospital Medical Center |
Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use
|
|
US9321803B2
(en)
|
2013-07-12 |
2016-04-26 |
Children's Hospital Medical Center |
Compositions and methods for inhibiting norovirus infection
|
|
ES2865825T3
(es)
|
2014-04-01 |
2021-10-18 |
Rubius Therapeutics Inc |
Procedimientos y composiciones para inmunomodulación
|
|
US20160160229A1
(en)
*
|
2014-12-09 |
2016-06-09 |
THC Farmaceuticals, Inc. |
Methods of producing antibody-rich cannabis and honeysuckle plants
|
|
EP3600397A4
(en)
|
2017-03-28 |
2021-01-27 |
Children's Hospital Medical Center |
NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
|
|
US20230023615A1
(en)
*
|
2019-12-13 |
2023-01-26 |
Dnalite Therapeutics, Inc. |
Compositions and methods for biological delivery vehicles
|
|
US20230051811A1
(en)
*
|
2019-12-20 |
2023-02-16 |
Translate Bio, Inc |
Rectal delivery of messenger rna
|